Pharma Capital
Why invest in NRT?

Novogen: Access latest PPT from Proactive's CEO Sessions

Dr James Garner talked clinical-stage programs with investors.
Novogen: Access latest PPT from Proactive's CEO Sessions
BigPicture
Dr James Garner, chief executive officer, Novogen

Novogen’s (ASX:NRT, NASDAQ:NVGN) chief executive officer, Dr James Garner, joined Proactive's CEO Sessions in Melbourne on Tuesday, 11th April.

Novogen is an emerging oncology drug developer with two clinical-stage programs.

The company's value proposition is to partner with big pharma for late-stage development to bring to market.

ACCESS THE FULL PRESENTATION HERE



Register here to be notified of future NRT Company articles
View full NRT profile

Novogen Timeline

View All

Related Articles

Cattle-herd-(Resized).jpg
If UniBio’s plans come to fruition it won’t be too long before the company orchestrates a major adjustment to the food-chain.

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.